Biohaven LTD

Biohaven Ltd. announced second quarter 2026 financial results and significant clinical advancements, including pivotal trial initiations for BHV-1300 and BHV-1400, and positive data for opakalim.

Biohaven Ltd. announced the appointment of John Yetimoglu to its Board of Directors, effective August 6, 2026, strengthening its Nominating and Governance Committee.

Biohaven Ltd. announces scientific leadership role transitions, promoting David Pirman, Ph.D., to EVP and Head of Discovery, and Bruce Car, Ph.D., to Chief Innovation Officer.

Biohaven presented positive clinical data for its epilepsy, immunology, and oncology programs, confirming pivotal trial initiations for 2026.

Biohaven Ltd. has amended its Equity Distribution Agreement with J.P. Morgan Securities LLC, allowing for potential sales of up to $350 million in common shares.

Biohaven Ltd. announced its first quarter 2026 financial results, highlighting progress in its epilepsy, obesity, and rare disease programs, with several pivotal trials set to initiate.

Biohaven Ltd. reported a net loss of $137.3 million for the second quarter of 2026, with operating expenses decreasing overall due to strategic reprioritization, while key drug candidates show promising clinical data.

Biohaven Ltd. reported a net loss of $130.5 million for Q1 2026, with a significant decrease in R&D expenses driven by strategic program prioritization and lower share-based compensation.

Biohaven Ltd. reported a reduced net loss for the nine months ended September 30, 2025, but faced significant clinical trial failures and regulatory setbacks for key programs, leading to a strategic pipeline reprioritization.

Biohaven reports a net loss reduction, secures $250M in new debt, but faces clinical setbacks for key programs while advancing others.

Biohaven Ltd. announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and strategic collaborations.

Biohaven Ltd. released its third quarter 2024 financial results, highlighting progress in clinical trials and strategic platform advancements.

Biohaven Ltd.'s 2024 10-K filing outlines the company's financial performance, clinical trial progress, and strategic initiatives across its immunology, neuroscience, and oncology programs.

Biohaven Pharmaceuticals outlines advancements in its diverse clinical and preclinical programs, including updates on ongoing trials and regulatory interactions.

Director Kishan Mehta was granted 68,693 stock options in Biohaven Ltd. as part of standard equity compensation.

Director Gregory Bailey was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director Michael Thomas Heffernan was granted 68,693 stock options in Biohaven Ltd. as part of standard compensation.

Director Irina Antonijevic was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director John W. Childs was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director Robert J. Hugin was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Biohaven Ltd. reports significant clinical progress in its immunology, epilepsy, and obesity programs, alongside a material adverse effect on stock value from an FDA approval failure.

Biohaven Ltd. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to its upcoming shareholder meeting.

Biohaven Ltd. is preparing for a potential commercial launch of troriluzole for spinocerebellar ataxia (SCA) in Q3 2025, while also advancing its pipeline across multiple therapeutic areas.

Biohaven Ltd. has filed a definitive proxy statement with the Securities and Exchange Commission.

Biohaven's proxy statement highlights the company's strategic shift towards immunology, neuroscience, and oncology, while also addressing challenges in the biopharma financial markets.

Woodline Partners LP has disclosed beneficial ownership of 7,660,280 common shares, representing 5.1% of Biohaven Ltd., as of June 30, 2026.

Janus Henderson Group Ltd. has reported beneficial ownership of 5.7% of Biohaven Ltd. common shares as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 11.7% of Biohaven Ltd. common shares, totaling 17,534,612 shares, as of March 31, 2026.

Suvretta Capital Management, LLC and affiliated entities reported a 7.8% beneficial ownership stake in Biohaven Ltd. as of December 31, 2025.

Janus Henderson Group plc has reported a 12.7% beneficial ownership stake in Biohaven Ltd., holding 16,803,459 common shares.

Janus Henderson Group plc has reported a 6.4% beneficial ownership stake in Biohaven Ltd., totaling 6,772,113 common shares, as of September 30, 2025.